Gritstone bio

Gritstone bio is a biotechnology company based in Oakland, California, with 233 employees. The company generates an estimated $100 million in annual revenue. Gritstone bio was founded by a team of distinguished scientists and advisors, and is led by a highly experienced and diverse leadership team. The company's board of directors is also comprised of seasoned and successful individuals. Gritstone bio focuses on developing next-generation vaccines for both cancer and infectious diseases. Their approach to immuno-oncology and infectious diseases centers on generating a therapeutic immune response by leveraging insights into the immune system's ability to recognize and destroy diseased cells by targeting select antigens. Initially focusing on tumor-specific neoantigens, Gritstone bio has expanded its programs to include viral antigens displayed on the surface of virus-infected cells. The company's research and development efforts are based on the understanding that the biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Gritstone bio believes this shared mechanism presents a significant opportunity to broaden the reach of immunotherapy and benefit more patients. For more information about Gritstone bio, please visit their website at gritstonebio.com.